Business Context and Reporting Period
This Form 8-K filing by Eyenovia, Inc. (trading symbol: EYEN) reports a material definitive agreement entered into on November 22, 2022. The filing details a new financing arrangement intended to provide working capital and support general corporate purposes. Note: The request metadata references "HYPERION DEFI, INC.", but the filing text explicitly identifies the registrant as Eyenovia, Inc.
Key Financial Metrics and Debt Structure
The filing discloses the following debt and equity terms:
- Total Loan Capacity: Up to $15.0 million in term loans.
- Initial Funding (Tranche 1): $10.0 million funded on November 22, 2022.
- Contingent Funding (Tranche 2): Up to $5.0 million available upon achievement of performance milestones, expiring July 31, 2023.
- Interest Rate: Variable, equal to the greater of (a) Prime Rate + 4.45% or (b) 7.00%.
- Repayment Terms: Interest-only payments for the first 12 months (extendable to 18 months if Tranche 2 is funded), followed by equal monthly principal and interest payments.
- Maturity Date: November 1, 2025.
- Final Payment: 4.25% of the advanced amount due at maturity or termination.
- Prepayment Fees: 3.0% (Year 1), 2.0% (Year 2), or 1.0% (Year 3) of the outstanding principal.
- Collateral: Substantially all of the Company's assets.
Material Changes and Equity Issuance
In connection with the loan agreement, the Company issued unregistered equity securities to the lenders:
- Shares Issued: 219,123 shares to Avenue Venture Opportunities Fund, L.P. and 328,684 shares to Avenue Venture Opportunities Fund II, L.P.
- Total Shares: 547,807 shares of Common Stock.
- Conversion Right: Lenders may convert up to $5.0 million of outstanding principal into Common Stock at 120% of the closing price on the Closing Date.
- Right to Invest: Lenders have the right to invest up to $1.0 million in future equity offerings for 18 months following the Closing Date.
Guidance, Risks, and Covenants
The filing outlines significant covenants and risks associated with the new debt:
- Covenants: The agreement limits additional indebtedness, liens (including a negative pledge on intellectual property), guaranties, mergers, asset sales, and transactions with affiliates.
- Events of Default: Include non-payment, covenant breaches, insolvency, bankruptcy, or a material adverse effect on the Company. Default allows the agent to accelerate payment and increase interest rates.
- Management Commentary: The Company intends to use proceeds for working capital and general corporate purposes. No specific revenue guidance or operational outlook was provided in this filing.
Investor Verification Checklist
- Verify the current stock price to calculate the conversion price (120% of the closing price on Nov 22, 2022) for the $5.0 million conversion option.
- Review the specific "performance milestones" required to unlock the $5.0 million Tranche 2 funding.
- Assess the impact of the 4.25% final payment and variable interest rate on future cash flow projections.
- Confirm the extent of assets pledged as collateral and any restrictions on future financing due to negative covenants.
- Check subsequent filings for the execution of the press release dated November 29, 2022, and any updates on Tranche 2 funding.